世界の血管線維腫治療薬市場 – 業界動向と2030年までの予測

血管線維腫治療薬市場の分析と規模

血管線維腫治療薬市場は、予測期間中に大幅な成長が見込まれています。血管線維腫は、線維芽細胞、コラーゲン、血管の局所的な過成長によって引き起こされます。結節性硬化症では、タンパク質ハマルチンをコードする結節性硬化症複合体 1 (TSC1) とタンパク質チュベリンをコードする結節性硬化症複合体 2 (TSC2) に変異が存在します。血管線維腫の最も一般的な治療法は手術です。血管線維腫治療薬は、血管線維腫をより迅速に治療するために不可欠です。

データブリッジ市場調査は、2023年から2030年の予測期間における血管線維腫治療薬市場の成長率を分析しています。血管線維腫治療薬市場の予想CAGRは、前述の予測期間において約7％になる傾向があります。市場は2022年に30億米ドルと評価され、2030年までに51億5000万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

血管線維腫治療薬市場の範囲とセグメンテーション

市場の定義

Angiofibroma is typically categorized as a group of lesions which includes fibrous papule, facial angiofibroma, adenoma sebaceum, periungual fibroma, pearly penile papule and Koenen's tumor. It is a benign vascular neoplasm nasal cavity tumour that is composed of dermal fibrous blood vessels. These diseases are usually diagnosed between the age group of 10 and 19 years old.  It is normally caused by the local overgrowth of fibroblasts, collagen, and blood vessels. Therefore, the early diagnosis and treatment is the most vital step for the diseases prevention.

Global Angiofibroma Drugs Market Dynamics

Drivers

• Growing Cases of Angiofibroma

The increasing inicidence of angiofibroma results for around 0.05% of all head and neck tumors. A frequency of 1:5,000-1:60,000 in otolaryngology patients has been witnessed. Thus, this boosts the market growth.

• Huge Demand For Diagnostic Tests

The increasing demand of several diagnostic tests such as genetic screening, skin biopsy, histopathology tests are driving the growth of the market.

Opportunities

• Increasing Demand for Retail Pharmacies

Increase in the number of angiofibroma drugs being delivered through these retail pharmacies and rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Furthermore, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

Restraints/Challenges

• Side Effects of angiofibroma drugs

There are several side effects that are associated with angiofibroma drugs. Angiofibroma drugs can lead to itchiness and may also bleed. Those associated with genetic syndromes result in facial disfigurement and stigmatization.

• High Cost

The huge expenditure of the treatment methods hamper the market growth. Several treatment options such as excision, cryotherapy, topical rapamycin, beta blockers are not so cost-effective and thus hinder the growth of the market.

This angiofibroma drugs market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the angiofibroma drugs market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Angiofibroma Drugs Market Scope

The angiofibroma drugs market  is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Excision
• Dermabrasion
• Beta Blockers Medication
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Angiofibroma Drugs Market Regional Analysis/Insights

The angiofibroma drugs market  is analyzed and market size insights and trends are provided by treatment, distribution channel and end-user as referenced above.

The major countries covered in the angiofibroma drugs market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.

Asia-Pacific dominates the market due to increased new research and developments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Angiofibroma Drugs Market Share Analysis

The angiofibroma drugs market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angiofibroma drugs market.

Key players operating in the angiofibroma drugs market  include:

• Galderma (Switzerland)
• Abbvie, Inc. (U.S.)
• Bausch Health Companies Inc. (Canada )
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• LEO Pharma A/S (Denmark)
• Novartis AG (Switzerland)
• Fresenius Kabi AG (Germany)
• Merck KGaA (Germany)
• Sanofi (France)

SKU-56901